格隆汇8月27日丨归创通桥(02190.HK)公告，8月27日耗资115万港元回购5万股。 ...

智通财经APP讯，归创通桥(02190)发布公告，于2025年8月27日斥资115.21万港元回购股份5万股，每股 回购价格为22.62-23.76港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 第 2 頁 共 7 頁 v 1.3.0 FF305 確認 呈交日期： 2025年8月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不 ...

2025年以来，沉寂已久的港股医药行业迎来强势反弹。富途显示，今年恒生医疗保健指数累计涨幅已突 破100%，不仅如同一记强心针点燃市场热情，更引发市场对行业走势的高度关注。 笔者认为，这场资本市场情绪升温的底层逻辑，绝非单纯的估值修复行情，更像是一场对行业拐点的集 体预判与布局。 随着集采政策步入优化调整的温和期，叠加国家层面持续释放鼓励真正创新产品研发、支持高端医疗器 械出海的政策红利，整个创新药械行业正悄然切换至以创新产品力角逐、全球化战略卡位及精益化运营 效能为核心的新赛道。 行业竞争格局的重塑，意味着能率先实现盈利突破的企业，将占据先发优势，进而驱动增长飞轮加速运 转。从成熟产品快速放量、运营效率持续优化，再到充沛盈利反哺创新投入，最终推动研发管线有序落 地并引领下一轮增长，而这也正是行业追寻的良性循环高阶形态。 刚刚发布2025年中期业绩的归创通桥，就交出了一份营收与利润双高增的亮眼答卷。 1、飞轮转动，交出营收利润双增高分卷 直观的财务数据足以说明归创通桥增长态势的强劲。财报显示，今年上半年，公司实现营收4.82亿元， 同比增长31.7%；净利润突破1.21亿元，同比大增76.0%，实现净利率25 ...

8月26日港股公司回购一览 | 代码 | 简称 | 回购股数 | 回购金额 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | （万港元） | （港元） | （港元） | （万港元） | | 00700 | 腾讯控股 | 89.90 | 55081.51 | 617.500 | 609.500 | 4389758.32 | | 01378 | 中国宏桥 | 203.40 | 5007.71 | 24.620 | 24.620 | 341759.47 | | 00011 | 恒生银行 | 20.00 | 2256.29 | 113.800 | 111.600 | 40862.91 | | 02282 | 美高梅中国 | 100.00 | 1613.91 | 16.290 | 15.950 | 11896.65 | | 02120 | 康宁医院 | 37.64 | 395.09 | 10.500 | 10.360 | 1245.43 | | 01651 | 津上机床中 国 | 9.50 | 25 ...

归创通桥(02190)发布公告，于2025年8月26日斥资118.1万港元回购5万股股份。 ...

智通财经APP讯，归创通桥(02190)发布公告，于2025年8月26日斥资118.1万港元回购5万股股份。 ...

公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總 ...

Summary of Key Points Core Viewpoint - On August 25, nine Hong Kong-listed companies conducted share buybacks, totaling 1.8064 million shares and an aggregate amount of HKD 577 million [1][2]. Group 1: Buyback Details - Tencent Holdings repurchased 895,000 shares for HKD 551 million, with a highest price of HKD 620.00 and a lowest price of HKD 608.50, bringing its total buyback amount for the year to HKD 43.347 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 22.697 million, with a highest price of HKD 113.90 and a lowest price of HKD 112.70, totaling HKD 38.606 million for the year [1][2]. - Beisen Holdings repurchased 200,000 shares for HKD 1.5988 million, with a highest price of HKD 8.09 and a lowest price of HKD 7.86, totaling HKD 34.2558 million for the year [1][2]. Group 2: Buyback Rankings - The highest buyback amount on August 25 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 22.697 million [1][2]. - In terms of buyback volume, Tencent Holdings led with 895,000 shares, followed by Qinqin Food at 320,000 shares and Beisen Holdings at 200,000 shares [1][2]. Group 3: Notable Events - Qinqin Food's buyback on this date marked its first buyback of the year, while Tencent Holdings has conducted multiple buybacks totaling HKD 43.347 billion for the year [2].

Group 1 - Business Development (BD) is a significant trend in the domestic medical device industry, with a notable increase in BD transactions for innovative drugs, reaching a total of $60.8 billion in the first half of the year, surpassing the total for 2024 [1] - The Chinese government is promoting the development of domestic medical devices, with a focus on high-end medical equipment and technologies such as medical robots and AI medical devices, as outlined in the announcement released in July 2025 [2] - There is a fundamental difference in the evaluation systems and investment models between innovative drugs and medical devices, with medical devices requiring more extensive market and academic investment for recognition in different markets [3] Group 2 - The current BD model for medical devices is not suitable for a simple license-out approach due to the high dependency on usage scenarios and the experience of practitioners, which complicates the management and control of subsequent clinical trials and registrations [4] - Although the current BD model for innovative drugs may not fit medical devices, there are still BD transactions occurring in the medical device sector, such as the joint venture established between China Medical Device Co., Ltd. and GE Healthcare China [5] - The recently published "Medical Device BD White Paper 2025" indicates that BD in the medical device sector encompasses various transaction activities, including technology licensing, joint development, and strategic investments, with a focus on the actual product deployment [6] Group 3 - The trend in medical device BD is shifting from single transactions to a more structured resource allocation system, with an increasing willingness among investors and partners to engage in the early stages of product development and registration [7]